The following articles (labelled with PubMed ID or TBD) are for your review
| PMID | Data | Article Title | Organization |
|---|
| 12482442 |
13 |
CRF ligands via Suzuki and Negishi couplings of 3-pyridyl boronic acids or halides with 2-benzyloxy-4-chloro-3-nitropyridine. |
Bristol-Myers Squibb |
| 12467632 |
13 |
Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands. |
Bristol-Myers Squibb |
| 12467631 |
32 |
Imidazo[4,5-b]pyridines as corticotropin releasing factor receptor ligands. |
Bristol-Myers Squibb |
| 11814780 |
18 |
Synthesis and evaluation of imidazo[1,5-a]pyrazines as corticotropin releasing hormone receptor ligands. |
Dupont Pharmaceuticals |
| 23465610 |
16 |
Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones. |
Bristol-Myers Squibb Research and Development |
| 23010264 |
14 |
[18F](R)-5-chloro-1-(1-cyclopropyl-2-methoxyethyl)-3-(4-(2-fluoroethoxy)-2,5-dimethyl phenylamino)pyrazin-2(1H)-one: introduction of N3-phenylpyrazinones as potential CRF-R1 PET imaging agents. |
Bristol-Myers Squibb |
| 22749422 |
43 |
Synthesis and structure-activity relationships of pyrido[3,2-b]pyrazin-3(4H)-ones and pteridin-7(8H)-ones as corticotropin-releasing factor-1 receptor antagonists. |
Bristol-Myers Squibb |
| 19552436 |
43 |
In vitro intrinsic clearance-based optimization of N3-phenylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. |
Bristol-Myers Squibb |
| 12904058 |
2 |
Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2. |
National Institutes of Health |
| 12361401 |
60 |
Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. |
Salk Institute |
| 10072680 |
32 |
Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies. |
Dupont Pharmaceuticals |
| 22196514 |
70 |
Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF¿?) receptor antagonists. |
Minase Research Institute |
| 21930387 |
60 |
Pyrazolo[1,5-a]pyrimidines, triazolo[1,5-a]pyrimidines and their tricyclic derivatives as corticotropin-releasing factor 1 (CRF¿?) receptor antagonists. |
Minase Research Institute |
| 21865047 |
48 |
6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists. |
Minase Research Institute |
| 21618986 |
65 |
Discovery of N-(1-ethylpropyl)-[3-methoxy-5-(2-methoxy-4-trifluoromethoxyphenyl)-6-methyl-pyrazin-2-yl]amine 59 (NGD 98-2): an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist. |
Neurogen |
| 21411322 |
8 |
Potential CRF1R PET imaging agents: N-fluoroalkyl-8-(6-methoxy-2-methylpyridin-3-yl)-2,7-dimethyl-N-alkylpyrazolo[1,5-a][1,3,5]triazin-4-amines. |
Bristol-Myers Squibb Research and Development |
| 20483614 |
56 |
5-arylamino-1,2,4-triazin-6(1H)-one CRF1 receptor antagonists. |
Bristol-Myers Squibb Research and Development |
| 20176478 |
26 |
Synthesis and structure-activity relationships of N3-pyridylpyrazinones as corticotropin-releasing factor-1 (CRF1) receptor antagonists. |
Bristol-Myers Squibb |
| 19954247 |
17 |
A strategy to minimize reactive metabolite formation: discovery of (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-[6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino]-5-oxo-4,5-dihydropyrazine-2-carbonitrile as a potent, orally bioavailable corticotropin-releasing factor-1 receptor antagonist. |
Bristol-Myers Squibb |
| 19552437 |
50 |
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists. |
Bristol-Myers Squibb |
| 16297619 |
24 |
Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands. |
Pharmaceutical Research Institute |
| 15509177 |
27 |
Synthesis, structure-activity relationships, and in vivo properties of 3,4-dihydro-1H-pyrido[2,3-b]pyrazin-2-ones as corticotropin-releasing factor-1 receptor antagonists. |
Bristol-Myers Squibb Pharmaceutical Research Institute |
| 15341489 |
34 |
Design, synthesis, and biological evaluation of 1,2,3,7-tetrahydro-6h-purin-6-one and 3,7-dihydro-1h-purine-2,6-dione derivatives as corticotropin-releasing factor(1) receptor antagonists. |
Pharmaceutical Research Institute |
| 11212103 |
4 |
The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type. |
Niddk |
| 10782669 |
7 |
Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor. |
Niddk |
| 10201844 |
24 |
Synthesis and biological activity of oxo-7H-benzo[e]perimidine-4-carboxylic acid derivatives as potent, nonpeptide corticotropin releasing factor (CRF) receptor antagonists. |
Agouron Pharmaceuticals |
| 10072679 |
86 |
Non-peptide corticotropin-releasing hormone antagonists: syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines. |
Dupont Pharmaceuticals |
| 9171885 |
7 |
Synthesis and oral efficacy of a 4-(butylethylamino)pyrrolo[2,3-d]pyrimidine: a centrally active corticotropin-releasing factor1 receptor antagonist. |
Pfizer |
| 27020524 |
29 |
Synthesis and evaluation of carbamate and aryl ether substituted pyrazinones as corticotropin releasing factor-1 (CRF?) receptor antagonists. |
Bristol-Myers Squibb |
| 26394156 |
11 |
Mechanism of MenE inhibition by acyl-adenylate analogues and discovery of novel antibacterial agents. |
Argonne National Laboratory |
| 9023294 |
3 |
Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. |
Sanofi Recherche |
| 9016352 |
9 |
Characterization of recombinant human P2X4 receptor reveals pharmacological differences to the rat homologue. |
Max-Planck Institute For Experimental Medicine |
Search and Browse
